Beginning Wednesday March 2, a new COVID-19 monoclonal antibody therapy, bebtelovimab, will be available for administration in Kettering Health Emergency Departments.
This agent has the advantage of a rapid 30-second injection and it is active against the Omicron variant of COVID-19.
The criteria for use have not changed. Patients must have a positive test for COVID-19 and symptom onset within the last 7 days to qualify.
Patients cannot be requiring supplemental oxygen or an increase in oxygen over baseline needs.
Ordering questions within EPIC detail the clinical criteria for therapy.
Questions can be directed to your Kettering Health inpatient pharmacy.